<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02135861</url>
  </required_header>
  <id_info>
    <org_study_id>201137</org_study_id>
    <nct_id>NCT02135861</nct_id>
  </id_info>
  <brief_title>A Method Validation Study for Evaluation of Novel Treatments Limiting Pulmonary Oedema in Cardiac Failure</brief_title>
  <official_title>An Evaluation of DCE-MRI Measures of Pulmonary Oedema and Vascular Permeability in Healthy Subjects and in Patients With Cardiac Failure: A Methods Validation Study for Evaluation of Novel Treatments Limiting Pulmonary Oedema in Cardiac Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transient receptor potential vanilloid 4 (TRPV4) channel blockade may be promising in the
      treatment of pulmonary oedema and dyspnoea in heart failure (HF) and acute decompensated
      heart failure (ADHF) patients by re-establishing the alveolar septal barrier. Dynamic
      contrast enhanced (DCE) Magnetic Resonance Imaging (MRI) is an established technique for
      assessing changes in vascular permeability and interstitial water volume. The aim of this
      study is to establish the potential utility of DCE-MRI as a novel endpoint for dose ranging
      and proof of mechanism studies of TRPV4 blockers. The DCE-MRI markers of vascular
      permeability and pulmonary oedema will be measured in subjects with HF (group 2) and healthy
      volunteers (HV) (group 1) at rest to determine if there is a difference between the two
      populations. Apart from this, exercise induced changes relative to rest in interstitial
      volume and exchange rate will be evaluated in both HV and subjects with HF. Additionally, the
      capability of DCE-MRI to detect changes in interstitial lung fluid in patients with acute
      decompensated heart failure (ADHF) (group 3) will be investigated. DCE-MRI markers of
      pulmonary oedema will be assessed when patients are initially hospitalized with ADHF and
      subsequently after receiving standard of care treatment to determine whether differences can
      be detected by this methodology.This study will enrol a sufficient number of subjects to have
      at least 24 subjects in Group 1 and 2 (group 1:12 HV and group 2: 12 subjects with HF) and
      atleast 5 subjects in Group 3. For each subject, the MRI data must be of sufficient quality
      to enable DCE-MRI modelling from 2 Sessions. For group 1 and 2, the subjects will have
      screening visit and 3 MRI sessions. For the first scanning session, subjects will undergo the
      baseline procedure. The second imaging session will occur approximately one week later to
      measure within subject variability. A third imaging session (which will be conducted in 2
      visits) will incorporate a bicycle exercise challenge prior to the MRI scan, and this third
      scan will be performed approximately one to three days after the second imaging session. For
      group 3: Screening will occur during hospitalization for eligibility. Session 1of MRI will be
      conducted while the subject is still hospitalized. Session 2 will be conducted within 4 weeks
      of the first scan, when the signs of pulmonary oedema are considered to be resolved. If a
      subject's pulmonary oedema has not resolved at Session 2, then the subject will be not be
      scanned by MRI at Session 2 and will be brought back for Session 3 up to 4 weeks after
      Session 2 for their second MRI.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 30, 2014</start_date>
  <completion_date type="Actual">February 22, 2017</completion_date>
  <primary_completion_date type="Actual">February 22, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Interstitial Volume (ve) in Heart Failure Participants and Healthy Volunteers at Baseline</measure>
    <time_frame>Day 1</time_frame>
    <description>Interstitial volume (ve) was measured by DCE-MRI. ve for total lung, left lung, right lung, left lung apical, left lung basal, right lung apical, right lung basal has been presented. Session 1 values were considered as Baseline values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exchange Rate (Ktrans) in Heart Failure Participants and Healthy Volunteers at Baseline</measure>
    <time_frame>Day 1</time_frame>
    <description>Exchange rate (Ktrans) was measured by DCE-MRI. Ktrans for total lung, left lung, right lung, left lung apical, left lung basal, right lung apical, right lung basal has been presented. Session 1 values were considered as Baseline values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interstitial Volume (ve) in Heart Failure Participants and Healthy Volunteers Before and Following Exercise</measure>
    <time_frame>Day 11</time_frame>
    <description>Interstitial volume (ve) was measured by DCE-MRI. ve for total lung, left lung, right lung, left lung apical, left lung basal, right lung apical, right lung basal before and following exercise has been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exchange Rate (Ktrans) in Heart Failure Participants and Healthy Volunteers Before and Following Exercise</measure>
    <time_frame>Day 11</time_frame>
    <description>Exchange rate (Ktrans) was measured by DCE-MRI. Ktrans for total lung, left lung, right lung, left lung apical, left lung basal, right lung apical, right lung basal before and following exercise has been presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Interstitial Volume (ve) in ADHF Participants</measure>
    <time_frame>Up to Week 8</time_frame>
    <description>Interstitial volume (ve) was measured by DCE-MRI. Three participants underwent 3 DCE-MRI scans. The data has been presented for individual participant in each session. The data presented below is only for total lung.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Exchange Rate (Ktrans) in ADHF Participants</measure>
    <time_frame>Up to Week 8</time_frame>
    <description>Exchange rate (Ktrans) was measured by DCE-MRI. Three participants underwent 3 DCE-MRI scans. The data has been presented for individual participant in each session. The data presented below is only for total lung.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Intra-subject Variability in Ve Between Session 1 and Session 2 of DCE-MRI</measure>
    <time_frame>Day 1 (Session 1) and Day 9 (Session 2)</time_frame>
    <description>Coefficient of variation (percentage) of intra-subject variability in Ve between Session 1 and Session 2 for total lung has been presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Intra-subject Variability in Ktrans Between Session 1 and Session 2 of DCE-MRI</measure>
    <time_frame>Day 1 (Session 1) and Day 9 (Session 2)</time_frame>
    <description>Coefficient of variation (percentage) of intra-subject variability in Ktrans between Session 1 and Session 2 for total lung has been presented.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Heart Failure, Congestive</condition>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will undergo MRI scanning conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 Tesla (T) system.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heart failure patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will undergo DCE-MRI scanning conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 T system.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute decompensated heart failure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will undergo DCE-MRI scanning conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 T system</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>DCE-MRI scans</intervention_name>
    <description>Subjects will be placed supine in the scanner and will be prepared for intravenous contrast agent administration. The contrast agent is administered using a power injector before imaging.</description>
    <arm_group_label>Acute decompensated heart failure</arm_group_label>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Heart failure patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Gadobutrol</intervention_name>
    <description>Gadobutrol at a dose less than or equal to 0.1 millimoles per kilogram (mmol/kg) will be given intravenously as a bolus using a power injector.</description>
    <arm_group_label>Acute decompensated heart failure</arm_group_label>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Heart failure patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or females over 18 years of age at the time of signing the informed consent.

          -  Body weight &gt;=50 kilogram (kg) and Body Mass Index (BMI) within the range 18.0-40.0
             kilogram/square meter (kg/m^2) (inclusive).

          -  Able to understand and comply with protocol requirements, instructions and protocol
             stated restrictions and is willing to take part in the imaging sessions.

          -  Capable of giving written informed consent, which includes compliance with the
             requirements and restrictions listed in the consent form.

        Inclusion Criteria for Heart Failure Group (group 2) - Established diagnosis of mild to
        moderate heart failure of any aetiology with symptoms defined as corresponding to the New
        York Heart Association (NYHA) class II or III.

        Inclusion Criteria for Healthy Volunteer Group (group 1)

        - Healthy as determined by a responsible and experienced physician, based on a medical
        evaluation including medical history, brief physical examination, clinical laboratory
        tests, and Electrocardiogram (ECG).

        Inclusion Criteria for Subjects with ADHF (Group 3)

          -  Male subjects OR female subjects of non reproductive potential as defined as
             pre-menopausal females with a documented tubal ligation or hysterectomy, or
             post-menopausal defined as 12 months of spontaneous amenorrhea [in questionable cases
             a blood sample with simultaneous follicle stimulating hormone (FSH) &gt; 40 million
             international units (MIU)/millilitre (mL) and oestradiol &lt; 40picogram (pg)/mL (&lt; 140
             pmol/L) is confirmatory.

          -  50 years of age or over at the time of signing the informed consent

          -  Hospitalized for the management of acute decompensated HF

          -  Presence of dyspnoea at rest or with minimal activity

          -  Presence of at least one of the following signs: Tachypnea with respiratory rate &gt;=20
             breaths/min or Rales or crackles audible on auscultation

          -  Chest x-ray with evidence of pulmonary congestion/oedema performed approximately
             within the last 48 hours (if not available - an additional research CXR may be
             requested)

          -  Have received at least one treatment with an intravenous diuretic prior to the first
             MRI scan

          -  Body weight &gt;= 50kg and BMI within the range 18-40 kg/m^2 (inclusive)

          -  Able to understand and comply with protocol requirements, instructions and
             protocol-stated restrictions and is willing to take part in the imaging sessions

          -  Capable of giving written informed consent, which includes compliance with the
             requirements and restrictions listed in the consent form

        Exclusion criteria:

        Exclusion Criteria for Heart Failure Group

          -  History of known primary pulmonary disease requiring current medication or other
             therapy.

          -  Orthopnoea of sufficient severity to preclude supine scanning as determined at
             screening.

          -  Unstable angina within the past 3 months.

          -  Uncontrolled hypertension (resting systolic Blood Pressure (BP) &gt;160 millimeters of
             mercury (mmHg) or resting diastolic BP &gt;100 mmHg).

          -  Resting hypoxia while breathing room air (Saturation of Oxygen [SaO2] &lt;88%). Exclusion
             Criteria for Healthy Volunteer Group and Heart Failure Groups

          -  Current smoker, defined as having smoked in the preceding 6 months.

          -  Contraindication for MRI scanning (as assessed by local MRI safety questionnaire)
             which includes but not limited to: Intracranial aneurysm clips or other metallic
             objects; Intra-orbital metal fragments that have not been removed ; Pacemakers or
             other implanted cardiac rhythm management devices and non-MRI compatible heart valves;
             Inner ear implants; and History of claustrophobia.

          -  Pregnant females as determined by positive urine human chorionic gonadotropin (HCG)
             test at screening or any scanning session.

          -  Positive test for drugs of abuse, not due to current prescription drugs as determined
             by the GSK Medical Monitor and principal investigator (PI), and alcohol screen.

          -  Estimated Creatinine Clearance (Cockcroft-Gault) &lt;60 millilitre (mL)/minute.

        Exclusion Criteria for Subjects with ADHF (Group 3)

          -  End-stage heart failure defined as requiring left ventricular assist devices,
             intra-aortic balloon pump or any type of mechanical support

          -  Chronic or intermittent renal support therapy (hemodialysis, ultrafiltration, or
             peritoneal dialysis)

          -  Ongoing or planned intravenous diuretic treatment within 1 hour of MRI scan
             appointment

          -  History of known primary pulmonary disease requiring current medication or other
             therapy

          -  Orthopnoea of sufficient severity to preclude supine scanning (as determined by a
             15-minute test of lying supine with or without the use of oxygen)

          -  Contraindication for MRI scanning (as assessed by local MRI safety questionnaire),
             which includes but is not limited to: Intracranial aneurysm clips (except Sugita) or
             other metallic objects OR intra-orbital metal fragments that have not been removed OR
             pacemakers or other implanted cardiac rhythm management devices and non-MRI compatible
             heart valves OR inner ear implants OR history of claustrophobia

          -  Estimated creatinine clearance (Cockcroft-Gault) &lt;40mL/minute

          -  Contraindication to MRI contrast agents

          -  Previous inclusion in a research and/or medical protocol involving nuclear medicine,
             PET or radiological investigations with significant radiation burden(a significant
             radiation burden being defined as 10 millisieverts (mSv) in addition to natural
             background radiation, in the previous 3 years including the dose from this study).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2GG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>April 24, 2014</study_first_submitted>
  <study_first_submitted_qc>May 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2014</study_first_posted>
  <results_first_submitted>February 20, 2018</results_first_submitted>
  <results_first_submitted_qc>October 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 27, 2019</results_first_posted>
  <last_update_submitted>October 16, 2018</last_update_submitted>
  <last_update_submitted_qc>October 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute decompensated heart failure</keyword>
  <keyword>heart failure</keyword>
  <keyword>MRI</keyword>
  <keyword>trpV4 channel inhibitors</keyword>
  <keyword>pulmonary oedema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Edema</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 8, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT02135861/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 28, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT02135861/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study included healthy volunteers (HV, group 1), participants (par) with heart failure (HF, group 2) and participants with acute decompensated heart failure (ADHF, group 3) who were hospitalized with evidence of pulmonary edema and received standard of care treatment.</recruitment_details>
      <pre_assignment_details>Dynamic Contrast Enhanced-Magnetic Resonance Imaging (DCE-MRI) markers were used to measure vascular permeability and pulmonary edema in HV and par. with HF. Forty one par. were enrolled and 36 entered the study. Three par. did not continue due to habitus and 2 par. did not participate as they required clinical investigations.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Healthy Volunteers</title>
          <description>Healthy volunteers were placed in supine position under the scanner and intravenous contrast agent was administered. Contrast agent was administered as a bolus using a power injector during the dynamic series. MRI scanning was conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 Tesla (T) system.</description>
        </group>
        <group group_id="P2">
          <title>Heart Failure Participants</title>
          <description>Heart failure participants were placed in supine position under the scanner and intravenous contrast agent was administered. Contrast agent was administered as a bolus using a power injector during the dynamic series. MRI scanning was conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 Tesla (T) system.</description>
        </group>
        <group group_id="P3">
          <title>Acute Decompensated Heart Failure Participants</title>
          <description>Acute Decompensated Heart Failure participants following hospitalization due to pulmonary oedema was placed in supine position under the scanner and intravenous contrast agent was administered. Contrast agent was administered as a bolus using a power injector during the dynamic series. MRI scanning was conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 Tesla (T) system.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Healthy Volunteers</title>
          <description>Healthy volunteers were placed in supine position under the scanner and intravenous contrast agent was administered. Contrast agent was administered as a bolus using a power injector during the dynamic series. MRI scanning was conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 Tesla (T) system.</description>
        </group>
        <group group_id="B2">
          <title>Heart Failure Participants</title>
          <description>Heart failure participants were placed in supine position under the scanner and intravenous contrast agent was administered. Contrast agent was administered as a bolus using a power injector during the dynamic series. MRI scanning was conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 Tesla (T) system.</description>
        </group>
        <group group_id="B3">
          <title>Acute Decompensated Heart Failure Participants</title>
          <description>Acute Decompensated Heart Failure participants following hospitalization due to pulmonary oedema was placed in supine position under the scanner and intravenous contrast agent was administered. Contrast agent was administered as a bolus using a power injector during the dynamic series. MRI scanning was conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 Tesla (T) system.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.8" spread="18.66"/>
                    <measurement group_id="B2" value="67.8" spread="13.42"/>
                    <measurement group_id="B3" value="79.3" spread="4.93"/>
                    <measurement group_id="B4" value="66.9" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>African American/African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Interstitial Volume (ve) in Heart Failure Participants and Healthy Volunteers at Baseline</title>
        <description>Interstitial volume (ve) was measured by DCE-MRI. ve for total lung, left lung, right lung, left lung apical, left lung basal, right lung apical, right lung basal has been presented. Session 1 values were considered as Baseline values.</description>
        <time_frame>Day 1</time_frame>
        <population>The Evaluable Population will include participants in safety population who are 40 years and older .The safety Population includes all enrolled participants who have initiated Session 1 DCE-MRI scan</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Volunteers</title>
            <description>Healthy volunteers were placed in supine position under the scanner and intravenous contrast agent was administered. Contrast agent was administered as a bolus using a power injector during the dynamic series. MRI scanning was conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 Tesla (T) system.</description>
          </group>
          <group group_id="O2">
            <title>Heart Failure Participants</title>
            <description>Heart failure participants were placed in supine position under the scanner and intravenous contrast agent was administered. Contrast agent was administered as a bolus using a power injector during the dynamic series. MRI scanning was conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 Tesla (T) system.</description>
          </group>
        </group_list>
        <measure>
          <title>Interstitial Volume (ve) in Heart Failure Participants and Healthy Volunteers at Baseline</title>
          <description>Interstitial volume (ve) was measured by DCE-MRI. ve for total lung, left lung, right lung, left lung apical, left lung basal, right lung apical, right lung basal has been presented. Session 1 values were considered as Baseline values.</description>
          <population>The Evaluable Population will include participants in safety population who are 40 years and older .The safety Population includes all enrolled participants who have initiated Session 1 DCE-MRI scan</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4946" spread="0.0362"/>
                    <measurement group_id="O2" value="0.3346" spread="0.0325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5078" spread="0.0349"/>
                    <measurement group_id="O2" value="0.3253" spread="0.0317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4960" spread="0.0417"/>
                    <measurement group_id="O2" value="0.3395" spread="0.0371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left lung apical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4952" spread="0.0339"/>
                    <measurement group_id="O2" value="0.3188" spread="0.0306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left lung basal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5349" spread="0.0397"/>
                    <measurement group_id="O2" value="0.3350" spread="0.0362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right lung apical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4865" spread="0.0392"/>
                    <measurement group_id="O2" value="0.3506" spread="0.0352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right lung basal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5045" spread="0.0444"/>
                    <measurement group_id="O2" value="0.3297" spread="0.0390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0029</p_value>
            <p_value_desc>estimates of total lung</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1600</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0600</ci_lower_limit>
            <ci_upper_limit>0.2600</ci_upper_limit>
            <other_analysis_desc>Ve was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <p_value_desc>estimates of left lung</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1825</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0855</ci_lower_limit>
            <ci_upper_limit>0.2795</ci_upper_limit>
            <other_analysis_desc>Ve was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0093</p_value>
            <p_value_desc>estimates of right lung</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1565</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0419</ci_lower_limit>
            <ci_upper_limit>0.2711</ci_upper_limit>
            <other_analysis_desc>Ve was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <p_value_desc>estimates of left lung apical</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1764</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0823</ci_lower_limit>
            <ci_upper_limit>0.2704</ci_upper_limit>
            <other_analysis_desc>Ve was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0010</p_value>
            <p_value_desc>estimates of left lung basal</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1999</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0894</ci_lower_limit>
            <ci_upper_limit>0.3103</ci_upper_limit>
            <other_analysis_desc>Ve was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0159</p_value>
            <p_value_desc>estimates of right lung apical</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1360</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0276</ci_lower_limit>
            <ci_upper_limit>0.2443</ci_upper_limit>
            <other_analysis_desc>Ve was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0064</p_value>
            <p_value_desc>estimates of right lung basal</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1748</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0535</ci_lower_limit>
            <ci_upper_limit>0.2961</ci_upper_limit>
            <other_analysis_desc>Ve was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Exchange Rate (Ktrans) in Heart Failure Participants and Healthy Volunteers at Baseline</title>
        <description>Exchange rate (Ktrans) was measured by DCE-MRI. Ktrans for total lung, left lung, right lung, left lung apical, left lung basal, right lung apical, right lung basal has been presented. Session 1 values were considered as Baseline values.</description>
        <time_frame>Day 1</time_frame>
        <population>The Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>Heart Failure Participants</title>
            <description>Heart failure participants were placed in supine position under the scanner and intravenous contrast agent was administered. Contrast agent was administered as a bolus using a power injector during the dynamic series. MRI scanning was conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 Tesla (T) system.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Volunteers</title>
            <description>Healthy volunteers were placed in supine position under the scanner and intravenous contrast agent was administered. Contrast agent was administered as a bolus using a power injector during the dynamic series. MRI scanning was conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 Tesla (T) system.</description>
          </group>
        </group_list>
        <measure>
          <title>Exchange Rate (Ktrans) in Heart Failure Participants and Healthy Volunteers at Baseline</title>
          <description>Exchange rate (Ktrans) was measured by DCE-MRI. Ktrans for total lung, left lung, right lung, left lung apical, left lung basal, right lung apical, right lung basal has been presented. Session 1 values were considered as Baseline values.</description>
          <population>The Evaluable Population</population>
          <units>Liter/minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2216" spread="0.0298"/>
                    <measurement group_id="O2" value="0.2353" spread="0.0273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2309" spread="0.0256"/>
                    <measurement group_id="O2" value="0.2173" spread="0.0236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2216" spread="0.0338"/>
                    <measurement group_id="O2" value="0.2474" spread="0.0309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left lung apical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2166" spread="0.0265"/>
                    <measurement group_id="O2" value="0.2161" spread="0.0244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left lung basal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2621" spread="0.0270"/>
                    <measurement group_id="O2" value="0.2225" spread="0.0249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right lung apical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2166" spread="0.0355"/>
                    <measurement group_id="O2" value="0.2528" spread="0.0326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right lung basal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2313" spread="0.0329"/>
                    <measurement group_id="O2" value="0.2431" spread="0.0301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.7381</p_value>
            <p_value_desc>estimates of total lung</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0137</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0968</ci_lower_limit>
            <ci_upper_limit>0.0695</ci_upper_limit>
            <other_analysis_desc>Ktrans was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6992</p_value>
            <p_value_desc>estimates of left lung</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.0136</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0580</ci_lower_limit>
            <ci_upper_limit>0.0852</ci_upper_limit>
            <other_analysis_desc>Ktrans was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5778</p_value>
            <p_value_desc>estimates of right lung</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0258</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1201</ci_lower_limit>
            <ci_upper_limit>0.0684</ci_upper_limit>
            <other_analysis_desc>Ktrans was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.9899</p_value>
            <p_value_desc>estimates of left lung apical</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.0005</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0738</ci_lower_limit>
            <ci_upper_limit>0.0747</ci_upper_limit>
            <other_analysis_desc>Ktrans was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2912</p_value>
            <p_value_desc>estimates of left lung basal</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.0396</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0360</ci_lower_limit>
            <ci_upper_limit>0.1153</ci_upper_limit>
            <other_analysis_desc>Ktrans was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4592</p_value>
            <p_value_desc>estimates of right lung apical</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0362</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1355</ci_lower_limit>
            <ci_upper_limit>0.0631</ci_upper_limit>
            <other_analysis_desc>Ktrans was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.7936</p_value>
            <p_value_desc>estimates of right lung basal</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0118</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1036</ci_lower_limit>
            <ci_upper_limit>0.0800</ci_upper_limit>
            <other_analysis_desc>Ktrans was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Interstitial Volume (ve) in Heart Failure Participants and Healthy Volunteers Before and Following Exercise</title>
        <description>Interstitial volume (ve) was measured by DCE-MRI. ve for total lung, left lung, right lung, left lung apical, left lung basal, right lung apical, right lung basal before and following exercise has been presented.</description>
        <time_frame>Day 11</time_frame>
        <population>The Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>Heart Failure Participants</title>
            <description>Heart failure participants were placed in supine position under the scanner and intravenous contrast agent was administered. Contrast agent was administered as a bolus using a power injector during the dynamic series. MRI scanning was conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 Tesla (T) system.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Volunteers</title>
            <description>Healthy volunteers were placed in supine position under the scanner and intravenous contrast agent was administered. Contrast agent was administered as a bolus using a power injector during the dynamic series. MRI scanning was conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 Tesla (T) system.</description>
          </group>
        </group_list>
        <measure>
          <title>Interstitial Volume (ve) in Heart Failure Participants and Healthy Volunteers Before and Following Exercise</title>
          <description>Interstitial volume (ve) was measured by DCE-MRI. ve for total lung, left lung, right lung, left lung apical, left lung basal, right lung apical, right lung basal before and following exercise has been presented.</description>
          <population>The Evaluable Population</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-exercise; Total lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4353" spread="0.0335"/>
                    <measurement group_id="O2" value="0.3205" spread="0.0292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-exercise; Total lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4568" spread="0.0307"/>
                    <measurement group_id="O2" value="0.3140" spread="0.0263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-exercise; Left lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4487" spread="0.0311"/>
                    <measurement group_id="O2" value="0.3121" spread="0.0267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-exercise; Left lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4832" spread="0.0266"/>
                    <measurement group_id="O2" value="0.3055" spread="0.0228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-exercise; Right lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4361" spread="0.0357"/>
                    <measurement group_id="O2" value="0.3294" spread="0.0311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-exercise; Right lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4534" spread="0.0355"/>
                    <measurement group_id="O2" value="0.3274" spread="0.0298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-exercise; Left lung apical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4272" spread="0.0335"/>
                    <measurement group_id="O2" value="0.3126" spread="0.0289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-exercise; Left lung apical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4449" spread="0.0257"/>
                    <measurement group_id="O2" value="0.2986" spread="0.0216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-exercise; Left lung basal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4890" spread="0.0318"/>
                    <measurement group_id="O2" value="0.3114" spread="0.0272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-exercise; Left lung basal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5310" spread="0.0323"/>
                    <measurement group_id="O2" value="0.3173" spread="0.0276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-exercise; Right lung apical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4343" spread="0.0378"/>
                    <measurement group_id="O2" value="0.3387" spread="0.0324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-exercise; Right lung apical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4504" spread="0.0358"/>
                    <measurement group_id="O2" value="0.3393" spread="0.0301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-exercise; Right lung basal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4400" spread="0.0347"/>
                    <measurement group_id="O2" value="0.3206" spread="0.0301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-exercise; Right lung basal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4591" spread="0.0367"/>
                    <measurement group_id="O2" value="0.3133" spread="0.0308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0156</p_value>
            <p_value_desc>estimates of total lung- Pre-exercise</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1148</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0236</ci_lower_limit>
            <ci_upper_limit>0.2061</ci_upper_limit>
            <other_analysis_desc>Ve was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0026</p_value>
            <p_value_desc>estimates of left lung- Pre-exercise</p_value_desc>
            <method>ANOVA</method>
            <method_desc>estimates of left lung- Pre-exercise</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1366</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0523</ci_lower_limit>
            <ci_upper_limit>0.2209</ci_upper_limit>
            <other_analysis_desc>Ve was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0328</p_value>
            <p_value_desc>estimates of right lung- Pre-exercise</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1067</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0094</ci_lower_limit>
            <ci_upper_limit>0.2040</ci_upper_limit>
            <other_analysis_desc>Ve was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0158</p_value>
            <p_value_desc>estimates of left lung apical-Pre-exercise</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1145</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0235</ci_lower_limit>
            <ci_upper_limit>0.2056</ci_upper_limit>
            <other_analysis_desc>Ve was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>estimates of left lung basal-Pre-exercise</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1776</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0917</ci_lower_limit>
            <ci_upper_limit>0.2635</ci_upper_limit>
            <other_analysis_desc>Ve was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0658</p_value>
            <p_value_desc>estimates of right lung apical-Pre-exercise</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.0956</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0067</ci_lower_limit>
            <ci_upper_limit>0.1979</ci_upper_limit>
            <other_analysis_desc>Ve was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0150</p_value>
            <p_value_desc>estimates of right lung basal-Pre-exercise</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1194</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0251</ci_lower_limit>
            <ci_upper_limit>0.2137</ci_upper_limit>
            <other_analysis_desc>Ve was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0015</p_value>
            <p_value_desc>estimates of total lung-Post-exercise</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1428</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0598</ci_lower_limit>
            <ci_upper_limit>0.2259</ci_upper_limit>
            <other_analysis_desc>Ve was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>estimates of left lung-Post-exercise</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1776</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1057</ci_lower_limit>
            <ci_upper_limit>0.2496</ci_upper_limit>
            <other_analysis_desc>Ve was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0114</p_value>
            <p_value_desc>estimates of right lung-Post-exercise</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1260</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0308</ci_lower_limit>
            <ci_upper_limit>0.2212</ci_upper_limit>
            <other_analysis_desc>Ve was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>estimates of left lung apical-Post-exercise</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1464</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0774</ci_lower_limit>
            <ci_upper_limit>0.2153</ci_upper_limit>
            <other_analysis_desc>Ve was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>estimates of left lung basal-Post-exercise</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.2137</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1266</ci_lower_limit>
            <ci_upper_limit>0.3008</ci_upper_limit>
            <other_analysis_desc>Ve was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0250</p_value>
            <p_value_desc>estimates of right lung apical-Post-exercise</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1111</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0151</ci_lower_limit>
            <ci_upper_limit>0.2071</ci_upper_limit>
            <other_analysis_desc>Ve was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0052</p_value>
            <p_value_desc>estimates of right lung basal-Post-exercise</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1458</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.0475</ci_lower_limit>
            <ci_upper_limit>0.2442</ci_upper_limit>
            <other_analysis_desc>Ve was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Exchange Rate (Ktrans) in Heart Failure Participants and Healthy Volunteers Before and Following Exercise</title>
        <description>Exchange rate (Ktrans) was measured by DCE-MRI. Ktrans for total lung, left lung, right lung, left lung apical, left lung basal, right lung apical, right lung basal before and following exercise has been presented.</description>
        <time_frame>Day 11</time_frame>
        <population>The Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>Heart Failure Participants</title>
            <description>Heart failure participants were placed in supine position under the scanner and intravenous contrast agent was administered. Contrast agent was administered as a bolus using a power injector during the dynamic series. MRI scanning was conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 Tesla (T) system.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Volunteers</title>
            <description>Healthy volunteers were placed in supine position under the scanner and intravenous contrast agent was administered. Contrast agent was administered as a bolus using a power injector during the dynamic series. MRI scanning was conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 Tesla (T) system.</description>
          </group>
        </group_list>
        <measure>
          <title>Exchange Rate (Ktrans) in Heart Failure Participants and Healthy Volunteers Before and Following Exercise</title>
          <description>Exchange rate (Ktrans) was measured by DCE-MRI. Ktrans for total lung, left lung, right lung, left lung apical, left lung basal, right lung apical, right lung basal before and following exercise has been presented.</description>
          <population>The Evaluable Population</population>
          <units>Liter/minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-exercise; Total lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2044" spread="0.0281"/>
                    <measurement group_id="O2" value="0.2567" spread="0.0247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-exercise; Total lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1841" spread="0.0221"/>
                    <measurement group_id="O2" value="0.2108" spread="0.0190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-exercise; Left lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2102" spread="0.0285"/>
                    <measurement group_id="O2" value="0.2525" spread="0.0245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-exercise; Left lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1785" spread="0.0200"/>
                    <measurement group_id="O2" value="0.1986" spread="0.0172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-exercise; Right lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2034" spread="0.0299"/>
                    <measurement group_id="O2" value="0.2550" spread="0.0263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-exercise; Right lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1926" spread="0.0269"/>
                    <measurement group_id="O2" value="0.2114" spread="0.0226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-exercise; Left lung apical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1856" spread="0.0293"/>
                    <measurement group_id="O2" value="0.2459" spread="0.0253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-exercise; Left lung apical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1621" spread="0.0199"/>
                    <measurement group_id="O2" value="0.1780" spread="0.0167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-exercise; Left lung basal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2552" spread="0.0296"/>
                    <measurement group_id="O2" value="0.2630" spread="0.0254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-exercise; Left lung basal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2060" spread="0.0227"/>
                    <measurement group_id="O2" value="0.2185" spread="0.0196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-exercise; Right lung apical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1934" spread="0.0281"/>
                    <measurement group_id="O2" value="0.2440" spread="0.0243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-exercise; Right lung apical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1892" spread="0.0267"/>
                    <measurement group_id="O2" value="0.2141" spread="0.0224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-exercise; Right lung basal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2181" spread="0.0319"/>
                    <measurement group_id="O2" value="0.2593" spread="0.0281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-exercise; Right lung basal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2052" spread="0.0284"/>
                    <measurement group_id="O2" value="0.2081" spread="0.0238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1730</p_value>
            <p_value_desc>estimates of total lung-Pre-exercise</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0524</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1292</ci_lower_limit>
            <ci_upper_limit>0.0244</ci_upper_limit>
            <other_analysis_desc>Ktrans was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2704</p_value>
            <p_value_desc>estimates of left lung-Pre-exercise</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0423</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1196</ci_lower_limit>
            <ci_upper_limit>0.0349</ci_upper_limit>
            <other_analysis_desc>Ktrans was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2072</p_value>
            <p_value_desc>estimates of right lung-Pre-exercise</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0515</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1334</ci_lower_limit>
            <ci_upper_limit>0.0303</ci_upper_limit>
            <other_analysis_desc>Ktrans was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1307</p_value>
            <p_value_desc>estimates of left lung apical-Pre-exercise</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0603</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1398</ci_lower_limit>
            <ci_upper_limit>0.0191</ci_upper_limit>
            <other_analysis_desc>Ktrans was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.8427</p_value>
            <p_value_desc>estimates of left lung basal-Pre-exercise</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0078</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0879</ci_lower_limit>
            <ci_upper_limit>0.0722</ci_upper_limit>
            <other_analysis_desc>Ktrans was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1848</p_value>
            <p_value_desc>estimates of right lung apical-Pre-exercise</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0506</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1269</ci_lower_limit>
            <ci_upper_limit>0.0257</ci_upper_limit>
            <other_analysis_desc>Ktrans was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3408</p_value>
            <p_value_desc>estimates of right lung basal-Pre-exercise</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0413</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1286</ci_lower_limit>
            <ci_upper_limit>0.0461</ci_upper_limit>
            <other_analysis_desc>Ktrans was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3682</p_value>
            <p_value_desc>estimates of total lung-Post-excercise</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0267</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0866</ci_lower_limit>
            <ci_upper_limit>0.0332</ci_upper_limit>
            <other_analysis_desc>Ktrans was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4531</p_value>
            <p_value_desc>estimates of left lung-Post-excercise</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.0201</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0744</ci_lower_limit>
            <ci_upper_limit>0.0342</ci_upper_limit>
            <other_analysis_desc>Ktrans was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5970</p_value>
            <p_value_desc>estimates of right lung-Post-excercise</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0188</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0909</ci_lower_limit>
            <ci_upper_limit>0.0533</ci_upper_limit>
            <other_analysis_desc>Ktrans was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5472</p_value>
            <p_value_desc>estimates of left lung apical-Post-excercise</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0159</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0693</ci_lower_limit>
            <ci_upper_limit>0.0375</ci_upper_limit>
            <other_analysis_desc>Ktrans was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6793</p_value>
            <p_value_desc>estimates of left lung basal-Post-excercise</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0125</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0742</ci_lower_limit>
            <ci_upper_limit>0.0491</ci_upper_limit>
            <other_analysis_desc>Ktrans was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4806</p_value>
            <p_value_desc>estimates of right lung apical-Post-excercise</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0249</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0964</ci_lower_limit>
            <ci_upper_limit>0.0466</ci_upper_limit>
            <other_analysis_desc>Ktrans was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.9379</p_value>
            <p_value_desc>estimates of right lung basal-Post-excercise</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0029</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0789</ci_lower_limit>
            <ci_upper_limit>0.0731</ci_upper_limit>
            <other_analysis_desc>Ktrans was fitted using a repeat measure ANOVA model with terms including participant population (HF or HV), visit (i.e. sessions), interaction of participant population and visit, with participant ID as block of the repeat factor</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Interstitial Volume (ve) in ADHF Participants</title>
        <description>Interstitial volume (ve) was measured by DCE-MRI. Three participants underwent 3 DCE-MRI scans. The data has been presented for individual participant in each session. The data presented below is only for total lung.</description>
        <time_frame>Up to Week 8</time_frame>
        <population>The safety population will include all enrolled participants who have initiated at least one session of DCE-MRI or Lung Ultrasound Scan</population>
        <group_list>
          <group group_id="O1">
            <title>Acute Decompensated Heart Failure Participants</title>
            <description>Acute Decompensated Heart Failure participants following hospitalization due to pulmonary oedema was placed in supine position under the scanner and intravenous contrast agent was administered. Contrast agent was administered as a bolus using a power injector during the dynamic series. MRI scanning was conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 Tesla (T) system.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interstitial Volume (ve) in ADHF Participants</title>
          <description>Interstitial volume (ve) was measured by DCE-MRI. Three participants underwent 3 DCE-MRI scans. The data has been presented for individual participant in each session. The data presented below is only for total lung.</description>
          <population>The safety population will include all enrolled participants who have initiated at least one session of DCE-MRI or Lung Ultrasound Scan</population>
          <units>Liter</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Par.1; Session 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.794"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Par.1; Session 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9577"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Par. 2; Session 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Par. 2; Session 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Par. 3; Session 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Par. 3; Session 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Par. 3 Session 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Exchange Rate (Ktrans) in ADHF Participants</title>
        <description>Exchange rate (Ktrans) was measured by DCE-MRI. Three participants underwent 3 DCE-MRI scans. The data has been presented for individual participant in each session. The data presented below is only for total lung.</description>
        <time_frame>Up to Week 8</time_frame>
        <population>The Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Acute Decompensated Heart Failure Participants</title>
            <description>Acute Decompensated Heart Failure participants following hospitalization due to pulmonary oedema was placed in supine position under the scanner and intravenous contrast agent was administered. Contrast agent was administered as a bolus using a power injector during the dynamic series. MRI scanning was conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 Tesla (T) system.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Exchange Rate (Ktrans) in ADHF Participants</title>
          <description>Exchange rate (Ktrans) was measured by DCE-MRI. Three participants underwent 3 DCE-MRI scans. The data has been presented for individual participant in each session. The data presented below is only for total lung.</description>
          <population>The Safety Population</population>
          <units>Liter/minute</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Par.1; Session 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Par.1; Session 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Par. 2; Session 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Par. 2; Session 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1952"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Par. 3; Session 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Par. 3; Session 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Par. 3 Session 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Intra-subject Variability in Ve Between Session 1 and Session 2 of DCE-MRI</title>
        <description>Coefficient of variation (percentage) of intra-subject variability in Ve between Session 1 and Session 2 for total lung has been presented.</description>
        <time_frame>Day 1 (Session 1) and Day 9 (Session 2)</time_frame>
        <population>The Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>Heart Failure Participants</title>
            <description>Heart failure participants were placed in supine position under the scanner and intravenous contrast agent was administered. Contrast agent was administered as a bolus using a power injector during the dynamic series. MRI scanning was conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 Tesla (T) system.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Volunteers</title>
            <description>Healthy volunteers were placed in supine position under the scanner and intravenous contrast agent was administered. Contrast agent was administered as a bolus using a power injector during the dynamic series. MRI scanning was conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 Tesla (T) system.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Intra-subject Variability in Ve Between Session 1 and Session 2 of DCE-MRI</title>
          <description>Coefficient of variation (percentage) of intra-subject variability in Ve between Session 1 and Session 2 for total lung has been presented.</description>
          <population>The Evaluable Population</population>
          <units>Percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5"/>
                    <measurement group_id="O2" value="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Intra-subject Variability in Ktrans Between Session 1 and Session 2 of DCE-MRI</title>
        <description>Coefficient of variation (percentage) of intra-subject variability in Ktrans between Session 1 and Session 2 for total lung has been presented.</description>
        <time_frame>Day 1 (Session 1) and Day 9 (Session 2)</time_frame>
        <population>The Evaluable Population</population>
        <group_list>
          <group group_id="O1">
            <title>Heart Failure Participants</title>
            <description>Heart failure participants were placed in supine position under the scanner and intravenous contrast agent was administered. Contrast agent was administered as a bolus using a power injector during the dynamic series. MRI scanning was conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 Tesla (T) system.</description>
          </group>
          <group group_id="O2">
            <title>Healthy Volunteers</title>
            <description>Healthy volunteers were placed in supine position under the scanner and intravenous contrast agent was administered. Contrast agent was administered as a bolus using a power injector during the dynamic series. MRI scanning was conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 Tesla (T) system.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Intra-subject Variability in Ktrans Between Session 1 and Session 2 of DCE-MRI</title>
          <description>Coefficient of variation (percentage) of intra-subject variability in Ktrans between Session 1 and Session 2 for total lung has been presented.</description>
          <population>The Evaluable Population</population>
          <units>Percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4"/>
                    <measurement group_id="O2" value="41.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events (SAEs) and AEs related to study procedure were planned to be collected from the start of study procedure and up to last visit (Up to Week 8)</time_frame>
      <desc>SAEs and non-serious AEs related to study procedure were planned to be reported for Safety Population</desc>
      <group_list>
        <group group_id="E1">
          <title>Healthy Volunteers</title>
          <description>Healthy volunteers were placed in supine position under the scanner and intravenous contrast agent was administered. Contrast agent was administered as a bolus using a power injector during the dynamic series. MRI scanning was conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 Tesla (T) system.</description>
        </group>
        <group group_id="E2">
          <title>Heart Failure Patients</title>
          <description>Heart failure participants were placed in supine position under the scanner and intravenous contrast agent was administered. Contrast agent was administered as a bolus using a power injector during the dynamic series. MRI scanning was conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 Tesla (T) system.</description>
        </group>
        <group group_id="E3">
          <title>Acute Decompensated Heart Failure</title>
          <description>Acute Decompensated Heart Failure participants following hospitalization due to pulmonary oedema was placed in supine position under the scanner and intravenous contrast agent was administered. Contrast agent was administered as a bolus using a power injector during the dynamic series. MRI scanning was conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 Tesla (T) system.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

